NKARTA INC. - COMMON

Nkarta Announces Updates to NKX019 and NKX101 Clinical Development Programs

07 окт 2021 16:01:00 Источник Nasdaq GlobeNewswire

Nkarta to Present Preclinical Data from Engineered NK Cell Platform at SITC 36th Annual Meeting

01 окт 2021 08:08:00 Источник Nasdaq GlobeNewswire

Nkarta to Participate at Upcoming Investor Conference

14 сен 2021 08:32:00 Источник Nasdaq GlobeNewswire

Nkarta Reports Second Quarter 2021 Financial Results and Business Progress

12 авг 2021 16:02:00 Источник Nasdaq GlobeNewswire

Nkarta Establishes New Combined NK Cell Therapy Manufacturing Facility / Company Headquarters

14 июл 2021 07:00:00 Источник Nasdaq GlobeNewswire

Nkarta to Present at Upcoming Investor Conference

16 июн 2021 07:00:00 Источник Nasdaq GlobeNewswire

Nkarta Therapeutics CEO, Paul Hastings, Named BIO Chair for 2021-2022 Term

14 июн 2021 07:01:00 Источник Nasdaq GlobeNewswire

Nkarta Announces June 2021 Investor Conference Schedule

25 май 2021 07:30:00 Источник Nasdaq GlobeNewswire

Nkarta Reports First Quarter 2021 Financial Results and Business Progress

13 май 2021 16:02:00 Источник Nasdaq GlobeNewswire

Nkarta Receives NKX019 IND Clearance from U.S. Food and Drug Administration for Treatment of Relapsed/Refractory B Cell Malignancies

28 апр 2021 08:02:00 Источник Nasdaq GlobeNewswire

Nkarta Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Business Progress

25 мар 2021 16:03:00 Источник Nasdaq GlobeNewswire

Nkarta Announces February and March 2021 Investor Conference Schedule

17 фев 2021 16:03:00 Источник Nasdaq GlobeNewswire